GastroAGI Logo
OverviewBlogsAbout
Trending TopicsConference

Gastroenterology Blogs - Page 2

GastroAGI Blog

Explore articles covering clinical insights, research updates, conference highlights, and practical discussions in gastroenterology.

Blogs

Stories, insights,
and updates.

Explore product updates, clinical insights, and emerging trends in
gastroenterology, all in one place.

Search gastroenterology blog articles
ACG 2026 Diverticulitis Guideline: CT Confirmation, Selective Antibiotics, and Smarter Follow-Up

ACG 2026 Diverticulitis Guideline: CT Confirmation, Selective Antibiotics, and Smarter Follow-Up

IntroductionDiverticulitis remains one of the most common reasons patients present with acute lower abdominal pain, outpatient GI consultation, emergency department visits, antibiotic exposure, colonoscopy referrals, and surgical discussions. Yet the management of diverticulitis has changed substantially over the past decade.The American College of Gastroenterology has now listed its July 2026 ACG Clinical Guideline on Colonic Diverticulitis, authored by Anne Peery, MD, MSCR, and colleagues. The guideline is available through the ACG guideline portal, with an accompanying highlights document summarizing key clinical recommendations.The most important message is that diverticulitis management is becoming more individualized. The update reinforces CT-based confirmation at first presentation, selective use of colonoscopy, selective rather than routine antibiotics in carefully chosen uncomplicated cases, and prevention strategies focused on diet, NSAID avoidance, weight management, physical activity, alcohol moderation, and smoking cessation.For GastroAGI readers, this is a highly practical guideline because it speaks directly to day-to-day decisions: Who needs CT? Who can avoid antibiotics? Who needs colonoscopy? When should surgery be discussed? And what advice should patients receive after recovery?

July 8, 2026•GastroAGI Team
Read Now316views
Anti-IL-10 Autoantibodies in IBD: What the 2026 NEJM Study Means for How You Classify and Treat Your Patients

Anti-IL-10 Autoantibodies in IBD: What the 2026 NEJM Study Means for How You Classify and Treat Your Patients

A 34-year-old woman with longstanding ulcerative colitis fails successive trials of mesalazine, azathioprine, and two biologics. Her disease remains active, her fecal calprotectin sits persistently above 1,000 μg/g, and her colonoscopy looks like she never had treatment. The standard algorithm has run out of moves. The 2026 NEJM study on anti–IL-10 autoantibodies may explain why - and what to do next.IBD has always been treated as two diseases (Crohn's disease and ulcerative colitis) shaped by environment, microbiome, and polygenic susceptibility. What the new NEJM paper makes clear is that a clinically meaningful subset of patients carries a third driver: functional autoimmunity against interleukin-10, the gut's primary immunosuppressive cytokine. These patients are phenotypically indistinguishable from conventional IBD by endoscopy or histology, but they are mechanistically distinct - and they may require a fundamentally different therapeutic approach. For the clinician managing a refractory case, this is not academic. The distinction has direct treatment implications that conventional IBD workup will never surface.

June 15, 2026•GastroAGI Team
Read Now26views
AI For Gastroenterology

AI For Gastroenterology

Gastroenterology is one of the most knowledge-dense fields in modern medicine. A gastroenterologist is expected to follow updates across hepatology, inflammatory bowel disease, endoscopy, pancreatobiliary disorders, gastrointestinal oncology, motility, nutrition, functional bowel disorders, and patient-centered communication. At the same time, new clinical guidelines, society recommendations, journal articles, conference abstracts, and therapeutic developments continue to expand at a pace that is difficult for any individual clinician, trainee, or researcher to track manually.This is where the idea of AI for gastroenterology becomes important.The future of medical AI is not simply about asking a chatbot a question. It is about building focused intelligence systems that understand the language, workflow, reasoning style, and safety requirements of a specific medical specialty. Gastroenterology needs more than generic artificial intelligence. It needs AI that can organize digestive disease knowledge, support gastroenterology education, assist with clinical reasoning, simplify complex GI topics, and communicate safely with patients.GastroAGI was created around that idea: a trusted, HIPAA-ready HI-AI intelligence platform built specifically for gastroenterology.It is designed not as a replacement for physicians, but as a structured intelligence layer for GI-focused learning, clinical context, and patient-friendly communication.

June 8, 2026•GastroAGI Team
Read Now141views
Clinical Decision Support in Gastroenterology: Why General Medical AI Keeps Falling Short

Clinical Decision Support in Gastroenterology: Why General Medical AI Keeps Falling Short

A GI fellow presents a 38-year-old with a third IBD flare in eight months - prior biologics failing, CRP climbing, and an upcoming infusion appointment that may need to change today. She types the case into a well-regarded general AI tool. The response is accurate, well-organized, and completely useless: it outlines the stepwise management of IBD as if she opened a textbook to page one. What she needed was a reasoned opinion on whether to step up to a JAK inhibitor, bridge with steroids, or expedite surgical review - and the confidence that the answer was grounded in current ECCO and ACG guidance, not a language model's best guess. She closes the tab.This scenario plays out dozens of times a day in GI practices that have tried to integrate AI into clinical workflows. The tools exist. They are polished, well-funded, and genuinely useful for a broad swath of medicine. Clinical decision support in gastroenterology, however, is a different problem - one that general-purpose platforms were not built to solve, and that their architects have not yet prioritized. Understanding where the gap sits and why it matters clinically is worth walking through carefully before choosing which tools earn a place in a GI workflow.

June 3, 2026•GastroAGI Team
Read Now33views
The Future of Gastroenterology Intelligence: How HIPAA-Ready, GI-Specialized AI Is Reshaping Care

The Future of Gastroenterology Intelligence: How HIPAA-Ready, GI-Specialized AI Is Reshaping Care

Gastroenterology has become an information-dense specialty. Clinicians are expected to synthesize expanding biomedical literature, rapidly changing GI guidelines, EHR data, pathology, imaging, endoscopy findings, and late-breaking conference updates while still making safe, time-sensitive decisions at the bedside and in the endoscopy suite. That challenge is not unique to GI, but it is especially visible in a field that spans hepatology, inflammatory bowel disease, GI oncology, screening and surveillance, pancreaticobiliary disease, motility, nutrition, and complex procedural care. Reviews of healthcare information overload and EHR-related cognitive burden have linked this environment to workflow strain and patient-safety risk, while PubMed alone now indexes more than 40 million biomedical citations. [1]The strategic opportunity is not “more AI” in the abstract. It is better clinical intelligence: HIPAA-ready AI that is specialized for gastroenterology, grounded in current society guidance, designed for human oversight, and capable of adapting its output to the user’s role. Recent reviews across NIH/PubMed, WJGNet, Gastroenterology, AMEgroups, and ScienceDirect describe real momentum for gastroenterology AI in endoscopy, IBD, hepatology, oncology, decision support, and education, but they also emphasize unresolved issues around hallucination, liability, bias, interoperability, and real-world validation. [2]The editorial implication is straightforward: generic search and general-purpose language models are not enough for high-stakes GI care. A safer path is GI-specialized, mode-adaptive, governed deployment. In practical terms, that means systems that can support gastroenterology education for fellows, GI clinical decision support for specialists, and responsible patient-facing communication—while respecting HIPAA, working within EHR interoperability standards, and remaining subordinate to clinician judgment. [3]

June 1, 2026•GastroAGI Team
Read Now16views
HER2-Positive Gastroesophageal Cancer in 2026: How HERIZON-GEA-01 Resets the First-Line Standard

HER2-Positive Gastroesophageal Cancer in 2026: How HERIZON-GEA-01 Resets the First-Line Standard

A 58-year-old male presents with progressive dysphagia, a 9 kg weight loss over three months, and a biopsy-confirmed HER2-positive gastroesophageal junction adenocarcinoma. Staging shows liver metastases. His PD-L1 combined positive score comes back at 2. Until last week, this was a trastuzumab-plus-chemotherapy case with a few nuanced arguments for adding pembrolizumab. The HERIZON-GEA-01 trial, published in the New England Journal of Medicine on May 28, 2026, changed the conversation for exactly this patient.HER2-positive disease accounts for approximately 20% of gastroesophageal adenocarcinoma (GEA) cases, and it has carried a disproportionately poor prognosis despite the availability of targeted therapy. Trastuzumab became the first-line backbone after the ToGA trial in 2010 - a result built on a modest overall survival benefit of roughly 2.7 months. For 16 years, that modest gain was the ceiling. The clinical question driving HERIZON-GEA-01 was straightforward: can a dual HER2-targeting bispecific antibody built to hit two non-overlapping epitopes simultaneously outperform a single-domain binder that has been the standard since gastroesophageal oncology was a subspecialty niche? And does adding a PD-1 checkpoint inhibitor extend that benefit further - including in patients whose tumours don't express PD-L1? Much like resmetirom becoming the first approved drug for NASH with fibrosis rewrote the MASLD treatment algorithm, the answer to both questions here reshapes the first-line standard for HER2-positive GEA. Based on zanidatamab HER2-positive gastroesophageal cancer first-line treatment data from 914 patients across three continents, the answer to both is yes.

June 1, 2026•GastroAGI Team
Read Now12views
FIB-4 in MASLD: When to Trust It, When It Fails, and What to Do in the Grey Zone

FIB-4 in MASLD: When to Trust It, When It Fails, and What to Do in the Grey Zone

Your patient is a 54-year-old woman with type 2 diabetes, a BMI of 33, and incidentally detected hepatic steatosis on abdominal ultrasound. You calculate her FIB-4 - it comes back at 1.1, which puts her in the low-risk category. You file it, reassure her, and plan a repeat in a year. Two years later she re-presents with fatigue and a platelet count of 118. Her FibroScan shows liver stiffness of 11.2 kPa. She has bridging fibrosis. The FIB-4 missed it. This post explains exactly why, and what your workup should have looked like.

May 25, 2026•GastroAGI Team
Read Now12views
Hepatic Encephalopathy in 2026: What the New ACG Guideline Changes About How You Diagnose, Treat, and Prevent It

Hepatic Encephalopathy in 2026: What the New ACG Guideline Changes About How You Diagnose, Treat, and Prevent It

Your cirrhotic patient is confused. Ammonia is elevated. You start lactulose and order a CT head out of habit. If that sequence sounds familiar, the new ACG hepatic encephalopathy guideline - published in March 2026 - is going to make you rethink several of those reflexes. Here is what changed, what stayed the same, and what it means for the patient in front of you tonight.Hepatic encephalopathy remains one of the most clinical challenging complications of cirrhosis - not because the diagnosis is obscure, but because the spectrum from covert to overt disease is wider than most clinicians manage systematically. The 2026 ACG guideline is the first to consolidate diagnosis, inpatient management, recurrence prevention, nutrition, TIPS-related HE, and transplant access into a single GRADE-based framework. Before this guideline, most clinicians were working from fragmented guidance across AASLD, EASL, and institutional protocols. The 24 recommendations now provide a unified, evidence-ranked reference for the full clinical journey.This is not a marginal update. Several recommendations directly contradict common practice.

May 22, 2026•GastroAGI Team
Read Now14views
ESGE Days 2026 Milan: What Every Gastroenterologist Needs to Take Back to Practice

ESGE Days 2026 Milan: What Every Gastroenterologist Needs to Take Back to Practice

Over 5,000 endoscopists descended on Milan's Allianz MiCo Convention Centre from May 14–16 for what has become the most important GI endoscopy congress in Europe. Three days, 44 educational sessions, live endoscopy from the Humanitas University Medical School, landmark trial data, and a record-breaking abstract haul. If you weren't there - or if you were and couldn't see everything - here is the clinical substance that matters.ESGE Days 2026 marked a turning point in several areas simultaneously: the obesity space was shaken by a head-to-head comparison between endoscopic sleeve gastroplasty and oral semaglutide, new randomised data landed for Crohn's strictures and gastroparesis, and the society formally launched three Special Interest Groups that will define the agenda for the next decade. The breadth of the scientific programme - from yoga in the endoscopy unit to robotic ERCP - reflected just how rapidly the field is evolving. Not every session changes practice immediately, but several clearly will.

May 21, 2026•GastroAGI Team
Read Now8views
Obesity is Plateauing in the West and Accelerating Everywhere Else: What That Means for Clinical Practice

Obesity is Plateauing in the West and Accelerating Everywhere Else: What That Means for Clinical Practice

A 34-year-old woman from a Pacific Island nation presents with a BMI of 38, type 2 diabetes diagnosed two years ago, and a haemoglobin of 9.4 g/dL. She has visible signs of iron and B12 deficiency alongside frank visceral obesity. She is, in nutritional terms, both overnourished and undernourished simultaneously. This is not an edge case anymore - it is the clinical reality of obesity in 2026 across much of the low- and middle-income world, and treating only one half of the picture will fail the patient.The largest epidemiological analysis of obesity ever published - the NCD Risk Factor Collaboration's 2026 study in Nature, tracking 232 million individuals across 200 countries from 1980 to 2024 - does not just tell us where obesity is. It tells us how fast it is moving, and which populations are now past the inflection point. The findings have direct implications for how gastroenterologists and GI clinicians approach obesity-related disease in patients coming from different epidemiological backgrounds.

May 20, 2026•GastroAGI Team
Read Now6views
Previous
12345
Next